Non-Alcoholic Steatohepatitis (NASH) Market by Expected Reach from $21,478 Million, By Leading & Growing at a CAGR of 58.4% from 2021 to 2025
Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/224
At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.
The Major Key Players Are:
• Allergan plc. (Tobira Therapeutics)
• Cadila Healthcare Limited
• Conatus Pharmaceuticals Inc.
• Galmed Pharmaceuticals Ltd
• Gemphire Therapeutics Inc.
• Genfit SA
• Gilead Sciences, Inc.
• Intercept Pharmaceuticals, Inc.
• Novartis International AG
• Shire Plc.
Buy Now @ https://www.alliedmarketresearch.com/checkout-final/6189ab9c34527b14e456217126191272
Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.
Key Findings of the Non-alcoholic Steatohepatitis (NASH) Market:
• Based on drug type, the selonsertib & cenicriviroc segment is expected to exhibit the fastest market growth, is projected to grow at a CAGR of 73.7% from 2021 to 2025.
• Based on sales channel, the retail pharmacy segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
• Based on sales channel, the online provider segment exhibited fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.
Read More Info @ https://www.linkedin.com/pulse/non-alcoholic-steatohepatitis-nash-market-promising-growth-panhale/?published=t
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis (NASH) Market by Expected Reach from $21,478 Million, By Leading & Growing at a CAGR of 58.4% from 2021 to 2025 here
News-ID: 1778837 • Views: 195
More Releases from Allied Market Research
Smart Inhalers Market is Like to Touch $1,406 Million by 2026
Smart Inhalers Market size was valued to be at $34 million in 2018 and is expected to increase during the forecast period to be at $1,406 million by 2026, registering a CAGR of 58.4% from 2019 to 2026. The inhalers segment accounted for more than half of the total market share in 2018. Smart inhalers are the small inhaler devices used for delivering several inhaled medications such as anticholinergics, glucocorticoids, and
Surgical Sutures Market On Position to Reach $5,255 Million by 2022
Surgical Sutures Market size accounted for $3,360 million in 2015, and is expected to reach $5,255 million by 2022, growing at a CAGR of 6.4% from 2016 to 2022. The sutures segment dominated the market in 2015 with more than four-fifths share. Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/1642 Global escalation in the number of hospitals, surge in the adoption of technologically advanced products, and increase in number of surgeries due
Internet of Things in Healthcare Market Like to Cross $332 Billion by 2027
The global internet of things in healthcare market was valued at $113.751 billion in 2019 and is expected to reach $332.672 billion by 2027, registering a CAGR of 13.20% from 2020 to 2027. The internet of things (IoT) is described as a network of physical devices that uses connectivity to enable the exchange of data. The internet of things in healthcare market is gaining popularity in the recent years owing
Breast Imaging Technologies Market Is Expected to Reach $4,502 Million by 2022
Breast Imaging Technologies Market Report, published by Allied Market Research, forecasts that the global breast imaging technologies market is expected to garner $4,502 million by 2022, registering a CAGR of 8.4% during the period 2016-2022.North America and Europe together accounted for over three-fourths market share in 2015. Ionizing breast imaging technology is expected to maintain its lead throughout the forecast period. The market is expected to be driven by the rise
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
Overview of NASH - Opportunity Analysis and Forecasts to 2026
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nonalcoholic Steatohepatitis (NASH) Market Worth US$ 20.0 Billion by 2025
New York, December 12: Market Research Engine has published a new report titled as “Non-Alcoholic Steatohepatitis (NASH) Market by Therapeutics (GFT505, Obeticholic Acid (INT-747), Liraglutide (Victoza) and Simtuzumab, Vitamin E, Pioglitazone, Placebo) - Global Industry Analysis, Trends and Forecast 2016 - 2025” Global Non-Alcoholic Steatohepatitis (NASH) market is expected to cross US$ 20.0 Billion by 2025 growing at a CAGR of more than 10.0% during given forecast period from 2016-2025. Browse Full
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will